Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2017 2
2019 5
2020 2
2021 6
2022 6
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacokinetics and bioequivalence of two pomalidomide capsules in healthy chinese subjects under fasting and fed conditions.
Liu Z, Xu Z, Gao Z, Ren Q, Chang T, Xue J, Yang H. Liu Z, et al. Invest New Drugs. 2023 Feb;41(1):60-69. doi: 10.1007/s10637-022-01320-9. Epub 2022 Nov 28. Invest New Drugs. 2023. PMID: 36441437
The aim of this study was to evaluate the bioequivalence and safety of the generic drug pomalidomide (Chia Tai Tianqing Pharmaceutical Group Co., Ltd) and its originator product Imnovid (Celgene Europe Ltd) in the fasting and fed states, respectively. ...
The aim of this study was to evaluate the bioequivalence and safety of the generic drug pomalidomide (Chia Tai Tianqing Pharmaceutica …
96-Week Treatment of Tenofovir Amibufenamide and Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients.
Liu Z, Jin Q, Zhang Y, Gong G, Wu G, Yao L, Wen X, Gao Z, Huang Y, Yang D, Chen E, Mao Q, Lin S, Shang J, Gong H, Zhong L, Yin H, Wang F, Hu P, Wu Q, Pan C, Jia W, Li C, Sun C, Niu J, Hou J; TMF Study Group. Liu Z, et al. J Clin Transl Hepatol. 2023 Jun 28;11(3):649-660. doi: 10.14218/JCTH.2022.00058. Epub 2022 Nov 1. J Clin Transl Hepatol. 2023. PMID: 36969889 Free PMC article.
A randomized, double-blind, single-dose, two-way, parallel phase I clinical study comparing the pharmacokinetics and safety of adalimumab injecta and Humira® in healthy Chinese male volunteers.
Wang Y, Gao Z, Liu Z, Liu G, Qu X, Chen J, Ren X, Xu Z, Yang H. Wang Y, et al. Expert Opin Biol Ther. 2022 Feb;22(2):225-234. doi: 10.1080/14712598.2021.1944097. Epub 2021 Jun 30. Expert Opin Biol Ther. 2022. PMID: 34134579 Clinical Trial.
This study compared the bioequivalence, immunogenicity and safety of adalimumab injecta (a biosimilar of Humira produced by Chia Tai Tianqing Pharmaceutical Group Co., Ltd) and Humira in healthy Chinese male subjects in a phase I clinical study. ...
This study compared the bioequivalence, immunogenicity and safety of adalimumab injecta (a biosimilar of Humira produced by Chia Tai Tian …
A randomized, double-blind, single-dose, parallel phase I clinical trial to compare the bioequivalence, immunogenicity, and safety of bevacizumab biosimilar and bevacizumab in healthy Chinese subjects.
Liu Z, Gao Z, Yang W, Zhang L, Xiao N, Qu D, Su Z, Xu K, Liu G, Wang Y, Ren Q, Yu S, Cheng Y, Zhou Y, Deng Q, Zhao Y, Wang Z, Yang H. Liu Z, et al. Expert Opin Drug Metab Toxicol. 2022 Jul-Aug;18(7-8):519-527. doi: 10.1080/17425255.2022.2113382. Epub 2022 Aug 18. Expert Opin Drug Metab Toxicol. 2022. PMID: 35961948 Clinical Trial.
A phase I clinical trial was conducted to compare the bioequivalence, immunogenicity, and safety of bevacizumab biosimilar (Chia Tai Tianqing Pharmaceutical Group Co., Ltd.) and Bevacizumab (Roche Diagnostics GmbH) in healthy Chinese males. ...
A phase I clinical trial was conducted to compare the bioequivalence, immunogenicity, and safety of bevacizumab biosimilar (Chia Tai Tian …
A randomized, double-blind, double-dummy, controlled, multicenter study of Qingzhong (tenofovir disoproxil fumarate) versus Viread for the treatment of chronic hepatitis B: First-stage results at week 48.
Liang RY, Xu JH, Si CW, Wang S, Shang J, Yu ZJ, Mao Q, Xie Q, Zhao W, Li J, Gao ZL, Wu SM, Tang H, Cheng J, Chen XY, Zhang WH, Wang H, Xu ZN, Wang L, Dai J, Yu YY. Liang RY, et al. Medicine (Baltimore). 2019 Aug;98(33):e16778. doi: 10.1097/MD.0000000000016778. Medicine (Baltimore). 2019. PMID: 31415381 Free PMC article. Clinical Trial.
Qingzhong and Viread, formulations of TDF commercialized by Jiangsu Chia-tai Tianqing Pharmaceutical Co Ltd and GlaxoSmithKline, respectively, have both been approved by the State Food and Drug Administration, China. ...
Qingzhong and Viread, formulations of TDF commercialized by Jiangsu Chia-tai Tianqing Pharmaceutical Co Ltd and GlaxoSmithKline, resp …
Tenofovir disoproxil fumarate in Chinese chronic hepatitis B patients: Results of a multicenter, double-blind, double-dummy, clinical trial at 96 weeks.
Chen XF, Fan YN, Si CW, Yu YY, Shang J, Yu ZJ, Mao Q, Xie Q, Zhao W, Li J, Gao ZL, Wu SM, Tang H, Cheng J, Chen XY, Zhang WH, Wang H, Xu ZN, Wang L, Dai J, Xu JH. Chen XF, et al. World J Clin Cases. 2021 Jun 26;9(18):4690-4699. doi: 10.12998/wjcc.v9.i18.4690. World J Clin Cases. 2021. PMID: 34222435 Free PMC article.
Qingzhong, a brand name of TDF, commercialized by Jiangsu Chia-tai Tianqing Pharmaceutical Co Ltd., and Viread, another brand name of TDF, commercialized by GlaxoSmithKline, have both been approved by the State Food and Drug Administration, China. ...
Qingzhong, a brand name of TDF, commercialized by Jiangsu Chia-tai Tianqing Pharmaceutical Co Ltd., and Viread, another brand name of …
[A phase II, single-arm, open-label, multicenter clinical study to evaluate the efficacy and safety of sofosbuvir combined with ribavirin in patients with genotype 2 chronic hepatitis C virus infection].
Gao YH, Li GM, Jin QL, Zhao YR, Jia ZS, Mao XR, Yang YF, Shang J, Wang GC, Xie W, Wu SM, Zhang MX, Hou JL, Li DL, Nan YM, Guan YJ, Zhu CX, Yuan YZ, Wei L. Gao YH, et al. Zhonghua Gan Zang Bing Za Zhi. 2019 May 20;27(5):352-357. doi: 10.3760/cma.j.issn.1007-3418.2019.05.006. Zhonghua Gan Zang Bing Za Zhi. 2019. PMID: 31177659 Clinical Trial. Chinese.
Objective: To evaluate the efficacy and safety of sofosbuvir (Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd.) combined with ribavirin in patients with genotype 2 chronic hepatitis C virus infection. ...
Objective: To evaluate the efficacy and safety of sofosbuvir (Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd.) combined with ribavi …
25 results